$LLY (-2.36%)
$HIMS (+1.27%)
$NOVO B (+0.8%)
$NVO (+1.04%)

• Revenue: $12.73B (est. $12.72B) ✅; +45%
• Adj. EPS: $3.34 (est. $3.46) ❌; +29% YoY
• Net Income (Adj): $3.00B (est. $2.72B) ✅

FY25 Guide"

• Adj. EPS: $20.78–$22.28 (Prior: $22.50–$24.00)
• Revenue: $58B–$61B (est. $59.57B)
• Performance Margin: 41.5%–43.5% (Adj)
• Effective Tax Rate: ~17% (Prior: ~16%)
• Other Expense (Reported): ($850M)–($750M)
• Capex/Manufacturing: Expanded; 4 new facilities announced
• Guidance Based On Existing Tariff, Environment

Key Product Revenue (Q1 YoY)

• Mounjaro: $3.84B (+113%)
• Zepbound: $2.31B (Est. $2.3B)
• Verzenio: $1.16B (+10%)
• U.S. Revenue: $8.49B (+49%)
• Intl Revenue: $4.24B (+38%)

Other Key Metrics:

• Gross Margin: 83.5% (Adj); +100 bps
• R&D Expenses: $2.73B (+8%); 21.5% of revenue
• SG&A: $2.47B (+26%)
• Acquired IPR&D: $1.57B (or $1.72/share)

Pipeline Progress:

• Orforglipron (oral GLP-1) Phase 3 success

• Donanemab awaiting CHMP outcome

• Jaypirca approved in EU for R/R CLL

• Lepodisiran shows 94% Lp(a) reduction

• Baricitinib shows positive adolescent AA results

• EBGLYSS: 50% clear skin at 3 years

• Omvoh: sustained remission in Crohn’s

Business Developments:

• Expanded Zepbound vial offerings + savings for self-pay
• LillyDirect expands Alzheimer’s access
• >$50B U.S. manufacturing investment (since 2020)

CEO David Ricks Commentary

• “We had a solid start to the year with 45% revenue growth led by Mounjaro and Zepbound. Our pipeline continues to deliver, and we are scaling manufacturing to meet growing global demand.”

$NOVO B (+0.8%)
$NVO (+1.04%)

Next entry 45

$NVO (+1.04%)
$NOVO B (+0.8%)

Second entry, next 55 + -

$NOVO B (+0.8%)
$NVO (+1.04%)

First entry

So I just realised that I've been investing for exactly 1 year and 1 week, so I thought this would be a good moment to reflect. I'm 36, the total portfolio size is 50k+ and the money isn't needed in short term. My portfolio summarised:

1. ETF core, 50% at minimum: $VDEV (-0.31%) and $VFEM (+0.58%) , recently added $EUE (+0.64%) as I see more potential in the EU than in the US in the short-medium term. I like how a combination of these 3 ETFs allows for more adaptability than simply putting everything in a world ETF. Plus, the TER is a bit lower.

2. Individual stocks, max 10 positions, only including companies that I understand and have faith in that they will perform well in the next couple of years. The goal is to at least match $IWDA (-0%) but preferably to make some additional gains. In summary:

Tech:

$NVDA (-0.83%) : committed after the post-Deepseek dip, will just wait out all the short-term turbulence

$AMZN (+0.59%) : doesn't need additional info.

$ASML (-0.42%) : ditto

$VRT (-2.02%) : see one of my previous posts on GQ. Bit too volatile for me now, but when the AI-hype picks up again, will perform well.

Health:

$NVO (+1.04%) : I have a lot of faith in the GLP1-narrative, stock is very undervalued

$LLY (-2.36%) : same at NVO, got pummeled hard recently but in longer term another good bet in the GLP1-race.

Divident:

$ALV (-2.76%) : popular German insurance company. Divident-wise, I have more faith in insurance companies than banks. Banks also face more headwinds due to fintech.

$ASRNL (+0.33%) : comparable to Allianz, solid, no-nonsense Dutch insurance company.

Bit more speculative:

$NU (-0.26%) : I think fintech has a lot of potential and NU was valued quite cheaply compared to US- or EU-based counterparts. Could benefit from US recession if USD evaluates.

What are your thoughts? What would you add or lose? I'm thinking of adding $GOOG (-0.7%) when the current downtrend subsides. Does make the portfolio more tech-heavy but all companies are internationally oriented (in case of US recession) and should outperform in the longer term.

Thanks in advance!

Today S&P reached an important support level and I started my buy strategy.

After that I bought back some $TROW (-0.1%) shares, $NVO (+1.04%) and $ENI (+2.25%)

And I was thinking to add to my portfolio one of those, $GOOG (-0.7%)
$META (-1.28%) or $MSFT (-0.01%) wich one would you choose?